Latham & Watkins Advises Icosavax in US$67.8 Million Registered Direct Offering of Common Stock
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, has announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 8,369,754 shares of its common stock at a purchase price of US$8.10 per share. The financing was led by new investor TCGX with participation by additional new investors including Logos Capital and Vivo Capital. All of the shares are to be sold by Icosavax. Icosavax expects to receive gross proceeds of approximately US$67.8 million from the offering.
Latham & Watkins LLP advised Icosavax in the offering, with a San Diego capital markets team led by partners Matt Bush and Cheston Larson with associates Shelby Harrison, Nadia Patiño, and Ryan Kazemaini.